Numis Securities Ltd reissued their buy rating on shares of Indivior PLC (LON:INDV) in a research report sent to investors on Friday. They currently have a GBX 450 ($5.61) price target on the specialty pharmaceutical company’s stock.
Several other equities analysts have also issued reports on INDV. Jefferies Group LLC lifted their price target on shares of Indivior PLC from GBX 370 ($4.61) to GBX 450 ($5.61) and gave the stock a buy rating in a report on Monday, November 7th. Deutsche Bank AG lifted their price target on shares of Indivior PLC from GBX 395 ($4.92) to GBX 400 ($4.98) and gave the stock a buy rating in a report on Thursday, November 3rd. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a GBX 500 ($6.23) price target on shares of Indivior PLC in a report on Friday, February 3rd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of GBX 388.57 ($4.84).
Shares of Indivior PLC (LON:INDV) opened at 353.00 on Friday. The company’s market cap is GBX 2.54 billion. The stock has a 50 day moving average price of GBX 295.62 and a 200-day moving average price of GBX 309.27. Indivior PLC has a 1-year low of GBX 126.60 and a 1-year high of GBX 377.00.
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia.